Compounds > vancomycin
Page last updated: 2024-08-21

vancomycin and ridinilazole

vancomycin has been researched along with ridinilazole in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Payne, L; Sattar, A; Thommes, P; Vickers, RJ; Warn, P1
Freeman, J; Vernon, J; Vickers, R; Wilcox, MH1
Chang, J; McDermott, LA; Snydman, DR; Thorpe, CM; Vickers, RJ; Walk, ST; Wick, J1
Chang, J; Kane, AV; Snydman, DR; Tai, A; Thorpe, CM; Vickers, RJ1
Collins, DA; Riley, TV1

Reviews

1 review(s) available for vancomycin and ridinilazole

ArticleYear
Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Letters in applied microbiology, 2022, Volume: 75, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Benzimidazoles; Clostridioides; Clostridioides difficile; Clostridium; Clostridium Infections; Fidaxomicin; Humans; Metronidazole; Pyridines; Vancomycin

2022

Trials

2 trial(s) available for vancomycin and ridinilazole

ArticleYear
Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Anti-Bacterial Agents; Benzimidazoles; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Pyridines; Ribotyping; Vancomycin

2018
Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.
    PloS one, 2018, Volume: 13, Issue:8

    Topics: Actinobacteria; Anti-Bacterial Agents; Benzimidazoles; Clostridioides difficile; Clostridium Infections; Cohort Studies; Discriminant Analysis; DNA, Bacterial; Feces; Firmicutes; Gastrointestinal Microbiome; Humans; Principal Component Analysis; Proteobacteria; Pyridines; Vancomycin

2018

Other Studies

2 other study(ies) available for vancomycin and ridinilazole

ArticleYear
SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:6

    Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Benzimidazoles; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Fidaxomicin; Gastrointestinal Tract; Mesocricetus; Microbial Sensitivity Tests; Plasma; Pyridines; Recurrence; Survival Analysis; Treatment Outcome; Vancomycin

2015
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Aminoglycosides; Anti-Bacterial Agents; Benzimidazoles; Ceftriaxone; Clostridioides difficile; Clostridium Infections; Drug Resistance, Multiple, Bacterial; Fidaxomicin; Fluoroquinolones; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Phenotype; Pyridines; Ribotyping; Vancomycin

2016